 Kazia Therapeutics Limited ASX: KZA; NASDAQ: KZIA, an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration FDA has granted Fast Track Designation FTD to Kazias paxalisib formerly GDC-0084 for the treatment of glioblastoma, the most common and most aggressive form of primary brain cancer. 